2021 San Antonio Breast Cancer VIRTUAL Symposium (SABCS)
(December 7-10th)
Identifying Homologous Recombination Deficiency in Breast Cancer: Genomic Instability Score Thresholds Differ in Breast Cancer Subtypes (TBCRC 008)
Kirsten M Timms, Lauren Lenz, Chris Neff, Cara Solimeno, Darl Flake, Judy C. Boughey, Matt P. Goetz, Andrea Richardson, Anna Maria Storniolo, Alexander Gutin, Roisin M. Connolly, Vered Stearns, Jerry S Lanchbury
Abstract: #P5-13-09
Poster Session 5: Friday, December 10th, 2021: 7-8:30am CT [Hall 1]
The Breast PreCancer Atlas DCIS Genomic Signatures Define Biology and Correlate with Clinical Outcomes: an Analysis of TBCRC 038 and RAHBT Cohorts
Siri H Strand, Belén Rivero-Gutiérrez, Kathleen E Houlahan, Jose A Seoane, Lorraine M King, Tyler Risom, Lunden A Simpson, Sujay Vennam, Aziz Khan, Timothy Hardman, Bryan Harmon, Fergus J Couch, Kristalyn Gallagher, Mark Kilgore, Shi Wei , Angela DeMichele, Tari King, Priscilla F McAuliffe, Julie Nangia, Joanna Lee, Jennifer Tseng, Anna Maria Storniolo, Alastair Thompson, Gaorav Gupta, Robyn Burns, Deborah J Veis, Katherine DeSchryver, Chunfang Zhu, Magdalena Matusiak, Jason Wang, Shirley X Zhu, Jen Tappenden, Daisy Yi Ding, Dadong Zhang, Jingqin Luo, Shu Jiang, Sushama Varma, Cody Straub, Sucheta Srivastava, Christina Curtis, Rob Tibshirani, Robert Michael Angelo, Allison Hall, Kouros Owzar, Kornelia Polyak, Carlo Maley, Jeffrey R Marks, Graham A. Colditz, E Shelley Hwang, Robert B West
Abstract: #GS4-07
Oral Presentation: Friday, December 10th, 2021: 10:15-10:30am CT [Hall 3]
Randomized Phase II Trial of Pembrolizumab/ Carboplatin vs Carboplatin Alone for Breast Cancer with Chest Wall Recurrence: TBCRC 044
Neelima Vidula, Rita Nanda, Kathy Miller, Leisha A. Emens, Vandana G. Abramson, Ben H. Park, Minetta C. Liu, Andrei Goga, and Hope S. Rugo
Abstract: #OT1-18-08
Ongoing Trials Poster Session 1: Wednesday, December 8th, 2021: 5-6:30pm CT [Hall 1]
Safety and Efficacy of a Tucatinib-Trastuzumab-Capecitabine Regimen for Treatment of Leptomeningeal Metastasis (LM) in HER2-Positive Breast Cancer: Results from TBCRC 049, a Phase 2 Non-Randomized Study
Rashmi K. Murthy, Barbara J O’Brien, Donald A. Berry, A. Singareeka-Raghavendra, Maria Gule Monroe, Jason Johnson, Jason White, Jennifer Childress, Jill Schwartz-Gomez, Michelle Melisko, Aki Morikawa, Sherise Ferguson, John F. de Groot, Ian Krop, Vicente Valero, Mothaffar Rimawi, Antonio Wolff, Debu Tripathy, Nancy U. Lin, Erica Stringer-Reasor
Abstract: #PD4-02
Spotlight Poster Discussion 4: Wednesday, December 8th, 2021: 5-6:30pm CT [Stars at Night Ballroom 3&4]
2021 American Society for Radiation Oncology (ASTRO) Annual Meeting
(October 24-27th in Chicago, IL)
A Phase II Randomized Trial of Adjuvant T-DM1 vs TH in Women with Stage I HER2 Positive Breast Cancer: Local Therapy Outcomes and Toxicity from the ATEMPT Trial (TBCRC 033)
Jennifer R. Bellon, Nabihah Tayob, Harold Burstein, Ann Partridge, Michelle DeMeo, Jordan Tralins, David Yang, Eric Winer, Ian Krop, and Sara Tolaney
Abstract: #65
Oral Presentation
2021 American Society for Clinical Oncology (ASCO) Annual Meeting
(all available on demand, beginning Friday, June 4th at 9am ET)
Multi-center Randomized Study of Pembrolizumab/carboplatin vs. Carboplatin Alone in Patients with Chest Wall Disease from Breast Cancer: TBCRC 044
Neelima Vidula, Rita Nanda, Kathy D. Miller, Leisha A. Emens, Paula R. Pohlmann, Vandana G. Abramson, Ben Ho Park, Minetta C. Liu, Andrei Goga, and Hope S. Rugo
Abstract: #TPS1111
Poster Session Title: Breast Cancer- Metastatic
Pharmacokinetic (PK) Analyses in CSF and Plasma from TBCRC 049, an Ongoing Trial to Assess the Safety and Efficacy of the Combination of Tucatinib, Trastuzumab and Capecitabine for the Treatment of Leptomeningeal Metastasis (LM) in HER2 Positive Breast Cancer
Erica Michelle Stringer-Reasor, Barbara Jane O'Brien, Ariel Topletz-Erickson, Jason B White, Mina Lobbous, Kristen Riley, Jennifer Childress, Kim LaMaster, Michelle E. Melisko, Aki Morikawa, John Frederick De Groot, Ian E. Krop, Vicente Valero, Mothaffar F. Rimawi, Antonio C. Wolff, Debu Tripathy, Nancy U Lin, and Rashmi Krishna Murthy
Abstract: #1044
Poster Session Title: Breast Cancer- Metastatic
A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer (TBCRC 050)
Erica Michelle Stringer-Reasor, Yufeng Li, Felicia Witherspoon, Jennifer M. Specht, Jesus Del Santo Anampa Mesias, Rita Nanda, Elizabeth Claire Dees, Antonio C. Wolff, Ian E. Krop, Nancy U. Lin, Mothaffar F. Rimawi, and Eddy Shih-Hsin Yang
Abstract: #TPS1098
Poster Session Title: Breast Cancer- Metastatic
2021 Publications
Chemotherapy-related Amenorrhea (CRA) after Adjuvant Ado-trastuzumab Emtansine (T-DM1) Compared to Paclitaxel in Combination with Trastuzumab (TH) (TBCRC 033: ATEMPT Trial)
Kathryn J. Ruddy, M.D., M.P.H., Yue Zheng, MSc. , Nabihah Tayob, Ph.D., Jiani Hu, MSc, Chau T. Dang, M.D., Denise A. Yardley, M.D., Steven J. Isakoff, M.D., Ph.D., Vicente V. Valero, M.D., Meredith G. Faggen, M.D., Therese M. Mulvey, M.D., Ron Bose, M.D., Ph.D., Tal Sella, M.D., Douglas J. Weckstein, M.D., Antonio C. Wolff, M.D., Katherine E. Reeder-Hayes, M.D., MBA, MSc., Hope S. Rugo, M.D., Bhuvaneswari Ramaswamy, M.D., Dan S. Zuckerman, M.D., Lowell L. Hart, M.D., Vijayakrishna K. Gadi, M.D., Ph.D., Michael Constantine, M.D., Kit L. Cheng, M.D., Frederick M. Briccetti, M.D., Bryan P. Schneider, M.D., A. Merrill Garrett, M.D., P. Kelly Marcom, M.D., Kathy S. Albain, M.D., Patricia A. DeFusco, M.D., Nadine M. Tung, M.D., Blair M. Ardman M.D., Rita Nanda M.D., Rachel C. Jankowitz, M.D., Mothaffar Rimawi, M.D., Vandana Abramson, M.D., Paula R. Pohlmann, M.D., Ph.D., MSc., Catherine Van Poznak, M.D., Andres Forero-Torres, M.D., Minetta Liu, M.D., Shoshana Rosenberg, Sc.D., M.P.H., Michelle K. DeMeo, B.S., Harold J. Burstein, M.D., M.P.H., Eric P. Winer, M.D., Ian E. Krop, M.D., Ph.D., Ann H. Partridge, M.D., Sara M. Tolaney, M.D., M.P.H.
Breast Cancer Res Treat. 2021 Aug; 189(1):103-110; PMID: 34120223.
Adjuvant Trastuzumab Emtansine vs Paclitaxel in Combination with Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial (TBCRC 033)
SM Tolaney, N. Tayob, C Dang, DA Yardley, SJ Isakoff, V Valero, M Faggen, T Mulvey, R Bose, J Hu, D Weckstein, AC Wolff, K Reeder-Hayes, HS Rugo, B Ramaswamy, D Zuckerman, L Hart, VK Gadi, M Constantine, K Cheng, F Briccetti, B Schneider, M Garrett, K Marcom, K Albain, P DeFusco, N Tung, B Ardman, R Nanda, RC Jankowitz, M Rimawi, V Abramson, PR Pohlmann, CV Poznak, A Forero-Torres, M Liu, K Ruddy, Y Zheng, SM Rosenberg, RD Gelber, L Trippa, W Barry, M DeMeo, H Burstein, A Partridge, EP Winer, I Krop
J Clin Oncol. 2021 Jul20;39(21):2375-2385; PMID: 34077270.
FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036
Steven P. Angus, Timothy J. Stuhlmiller, Gaurav Mehta, Samantha M. Bevill, Daniel R. Goulet, J. Felix Olivares-Quintero, Michael P. East, Maki Tanioka, Jon S. Zawistowski, Darshan Singh, Noah Sciaky, Xin Chen, Xiaping He, Naim U. Rashid, Lynn Chollet-Hinton, Cheng Fan, Matthew G. Soloway, Patricia A. Spears, Stuart Jefferys, Joel S. Parker, Kristalyn K. Gallagher, Andres Forero-Torres, Ian E. Krop, Alastair M. Thompson, Rashmi Murthy, Michael L. Gatza, Charles M. Perou, H. Shelton Earp, Lisa A. Carey, and Gary L. Johnson
NPJ Breast Cancer, 2021 May 12;7(1):51; PMID: 33980863.